{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosiglitazone+therapy&page=2",
    "query": {
      "intervention": "Rosiglitazone therapy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosiglitazone+therapy&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rosiglitazone+therapy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T03:20:41.542Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00110851",
      "title": "Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "PN2034",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wellstat Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "21 Years to 72 Years"
      },
      "enrollment_count": 90,
      "start_date": "2005-04",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-08-23",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 20,
      "location_summary": "Waterbury, Connecticut • DeLand, Florida • Hollywood, Florida + 16 more",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Longwood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110851"
    },
    {
      "nct_id": "NCT00819910",
      "title": "Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertriglyceridemia in Type 4 Hyperlipidemia",
        "Non Diabetic Subjects With Normoglycemia"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Rosiglitazone)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Fenofibrate)",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ahmad Slim",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2008-09",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2014-04-24",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00819910"
    },
    {
      "nct_id": "NCT00490568",
      "title": "Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": "91 Years",
        "sex": "ALL",
        "summary": "51 Years to 91 Years"
      },
      "enrollment_count": 1461,
      "start_date": "2007-08-08",
      "completion_date": "2009-06-01",
      "has_results": true,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 41,
      "location_summary": "Litchfield Park, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more",
      "locations": [
        {
          "city": "Litchfield Park",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00490568"
    },
    {
      "nct_id": "NCT00274495",
      "title": "Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C Infection",
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone and Pegasys/Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-01",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2007-11-01",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00274495"
    },
    {
      "nct_id": "NCT00081328",
      "title": "Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type II"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Lifestyle Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 699,
      "start_date": "2004-05",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081328"
    },
    {
      "nct_id": "NCT00358124",
      "title": "Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 220,
      "start_date": "2001-01",
      "completion_date": "2002-06",
      "has_results": false,
      "last_update_posted_date": "2011-01-11",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358124"
    },
    {
      "nct_id": "NCT00511823",
      "title": "The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nausea and Vomiting, Chemotherapy-Induced"
      ],
      "interventions": [
        {
          "name": "casopitant",
          "type": "DRUG"
        },
        {
          "name": "dolasetron",
          "type": "DRUG"
        },
        {
          "name": "granisetron",
          "type": "DRUG"
        },
        {
          "name": "rosiglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 16,
      "start_date": "2007-07-23",
      "completion_date": "2007-09-21",
      "has_results": false,
      "last_update_posted_date": "2017-08-03",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511823"
    },
    {
      "nct_id": "NCT00000620",
      "title": "Action to Control Cardiovascular Risk in Diabetes (ACCORD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis",
        "Cardiovascular Diseases",
        "Hypercholesterolemia",
        "Hypertension",
        "Diabetes Mellitus, Type 2",
        "Diabetes Mellitus",
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "Anti-hyperglycemic Agents",
          "type": "DRUG"
        },
        {
          "name": "Anti-hypertensive Agents",
          "type": "DRUG"
        },
        {
          "name": "Blinded fenofibrate or placebo plus simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "40 Years to 79 Years"
      },
      "enrollment_count": 10251,
      "start_date": "1999-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-22",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 6,
      "location_summary": "Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000620"
    },
    {
      "nct_id": "NCT00607945",
      "title": "Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant",
          "type": "DRUG"
        },
        {
          "name": "conjugated linoleic acid (CLA)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-01",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00607945"
    },
    {
      "nct_id": "NCT00150410",
      "title": "Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Inhaled insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 626,
      "start_date": "2003-01",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2008-10-31",
      "last_synced_at": "2026-10-05T03:20:41.542Z",
      "location_count": 88,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 72 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Searcy",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00150410"
    }
  ]
}